Deepull Adds Two New Executive Team Members

deepull has appointed Dr. Kimberle Chapin as chief medical officer and Wade Stevenson as chief marketing and sales officer.
 
“Kim and Wade are joining at an important time for the business as it progresses its automated sepsis diagnostic test,” deepull Co-Founder/CEO Jordi Carrera said. “Their combined expertise will be pivotal in the development of deepull’s direct-from-blood, rapid diagnostics system.”
 
Chapin is a professor of Medicine and Pathology and Laboratory Medicine at the Warren Alpert School of Medicine at Brown University. She is experienced in the clinical management of laboratory diagnostics, with a focus on infectious diseases. Previously, Chapin worked as chief medical officer at Cepheid and for 17 years was director of Clinical Microbiology and Molecular Diagnostics for Infectious Diseases for Lifespan Academic Medical Center.

Chapin earned her medical degree and MSc. in molecular genetics and microbiology from the University of Massachusetts, and her bachelor of science degree in biology from Boston College.

“deepull’s innovative approach to rapid pathogen identification has the potential to provide a marked improvement over standard of care testing for patients with sepsis,” Chapin stated. “I am looking forward to sharing my experience from the laboratory and clinical practice to help deliver improved patient outcomes through early detection.”
 
Stevenson is a seasoned commercial leader and marketing executive with more than 25 years’ experience in infectious diseases, molecular diagnostics, and pharmaceuticals. He spent 18 years at global diagnostics company BioFire Diagnostics, latterly bioMérieux, in various roles. As vice president of North America Clinical Marketing, he was responsible for the global commercial success of the BioFire franchise. Stevenson’s previous roles include vice president, Marketing, of Roche’s U.S. molecular laboratory, where he supervised a broad portfolio of molecular in-vitro diagnostic assays and instruments as well as next-generation sequencing products.

Stevenson earned his MBA from the University of North Carolina Kenan-Flagler Business School, and a bachelor of science degree in zoology from Brigham Young University.
 
“I have been working in the diagnostics space for many years and believe deepull’s approach could transform hospital laboratory testing and support compliance with sepsis guidelines. The next few months will be important as we drive forward with the development of this rapid diagnostics solution and build out our commercial strategy,” Stevenson said.
 
deepull is a diagnostics company developing culture-free diagnostic solutions for sepsis and acute infections. Founded in 2020 in Barcelona by the founders of STAT-Dx (sold to QIAGEN in 2018), deepull has assembled a team of experts to create rapid and accessible diagnostic solutions. deepull is developing a one-hour, direct-from-blood PCR test targeting 95% of sepsis-causing pathogens. The test will extract total microbial DNA from 8mL of whole blood and include 50 reportable results. The test runs on the deepull UllCORE instrument; a benchtop system with sample-to-result automation being designed to meet the needs of any hospital clinical laboratory.